ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 257 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $11,000 | -90.0% | 149 | -88.6% | 0.00% | -90.9% |
| Q4 2021 | $110,000 | -53.4% | 1,307 | -50.2% | 0.01% | -8.3% |
| Q3 2021 | $236,000 | +47.5% | 2,623 | +56.1% | 0.01% | +71.4% |
| Q2 2021 | $160,000 | -28.9% | 1,680 | -15.1% | 0.01% | -41.7% |
| Q1 2021 | $225,000 | -11.4% | 1,979 | -36.1% | 0.01% | -25.0% |
| Q3 2020 | $254,000 | +229.9% | 3,098 | +218.4% | 0.02% | +220.0% |
| Q2 2020 | $77,000 | +1440.0% | 973 | +826.7% | 0.01% | – |
| Q1 2020 | $5,000 | 0.0% | 105 | -15.3% | 0.00% | – |
| Q3 2019 | $5,000 | -87.8% | 124 | -79.3% | 0.00% | -100.0% |
| Q1 2019 | $41,000 | +583.3% | 598 | +321.1% | 0.00% | +200.0% |
| Q4 2018 | $6,000 | +100.0% | 142 | +91.9% | 0.00% | – |
| Q4 2017 | $3,000 | -50.0% | 74 | -25.3% | 0.00% | -100.0% |
| Q2 2017 | $6,000 | – | 99 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |